Supplemental Table for:
Missed Detection of KRAS Mutations and Other Alterations Predicted to Confer Lack of Benefit from EGFR Antibody Therapy in Advanced Colorectal Cancer
Alexa B. Schrock et al.

Table S1. Primary vs. metastatic biopsy site for CRC cases analyzed by CGP categorized by genomic alteration.

	Primary	Metastasis	Total cases with data	% Metastatic
NRAS amp	1	5	6	83.3
EGFR EC	2	8	10	80.0
HRAS amp	1	4	5	80.0
BRAF amp	1	3	4	75.0
ERBB2 EC	4	11	15	73.3
MEK1 mut	15	26	41	63.4
RTK rearr	6	9	15	60.0
HRAS mut	3	4	7	57.1
MET amp	17	22	39	56.4
KRAS amp	32	41	73	56.2
PTEN del	63	75	138	54.3
FLT3 amp	157	159	316	50.3
ERBB2 trunc	2	2	4	50.0
BRAF rearr	4	4	8	50.0
ERBB2 amp	68	66	134	49.3
BRAF non-V600 mut	47	41	88	46.6
NRAS mut	86	75	161	46.6
KRAS G12/13 mut	1042	880	1922	45.8
KRAS non-G12/13 mut	154	120	274	43.8
PTEN trunc	85	65	150	43.3
PIK3CA mut	419	314	733	42.8
ERBB2 KD	43	25	68	36.8
BRAF V600 mut	153	77	230	33.5
ARAF mut	2	1	3	33.3
ARAF amp	3	0	3	0.0
RAS/RAF wild-type	851	792	1643	48.2
All cases	2334	2009	4343	46.3

Mut: mutation; amp: amplification; del: deletion; trunc: truncation; WT: wild-type; EC: extracellular domain; KD: kinase domain.